Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck’s Heplisav Gets FDA Clinical Hold

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III subject diagnosed with Wegener’s granulomatosis, a rare blood vessel inflammation.

You may also be interested in...



US FDA Tweaks IND Clinical Hold Policy As Number Of Holds Rises

Clinical holds by the US FDA have risen 36% since 2014.

Pfizer TLR-9 Adjuvant With Prevnar In HIV Patients Hints At Post-Wyeth Vaccine Opportunities

Danish academic trial has been looking at how Pfizer/Coley adjuvant can enhance effect of standard Wyeth Prevnar formulation.

Pfizer TLR-9 Adjuvant With Prevnar In HIV Patients Hints At Post-Wyeth Vaccine Opportunities

Danish academic trial has been looking at how Pfizer/Coley adjuvant can enhance effect of standard Wyeth Prevnar formulation.

Related Content

Topics

UsernamePublicRestriction

Register

PS067420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel